Arcutis appoints Amit Munshi to Board; founder Chaudhuri retires, retains consulting role

Arcutis Biotherapeutics, Inc.

Bhaskar Chaudhuri retired from Board and Compensation Committee chair on Dec 3, 2025; no disagreement.
Chaudhuri entered consulting agreement through June 30, 2027 with hourly rate; options continue to vest.
Amit Munshi appointed Class II director and Compensation Committee chair effective Dec 4, 2025.
Munshi received initial option for 16,502 shares; eligible for prorated annual equity of ~$300,000 and cash retainers of $50,000 (Board) + $15,000 (chair).
Munshi previously served as CEO of Arena Pharmaceuticals (acquired by Pfizer for $6.7B) and Orna Therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.